Location History:
- Outremont, CA (2015 - 2019)
- Québec, CA (2019)
- Montreal, CA (2010 - 2023)
Company Filing History:
5 out of 183 
2 out of 14 
1 out of 1 Years Active: 2010-2023
Title: Claude Perreault: Innovator in Cancer Immunotherapy
Introduction
Claude Perreault is a distinguished inventor based in Outremont, Canada. He has made significant contributions to the field of cancer immunotherapy, holding a total of six patents. His work focuses on identifying tumor-specific antigens, which play a crucial role in the immune response against cancer.
Latest Patents
One of his latest patents is a proteogenomic-based method for identifying tumor-specific antigens. This method utilizes RNA-sequencing data from cancer and normal-matched samples to identify non-tolerogenic tumor-specific antigens. These antigens are derived from various genomic regions and are essential for the recognition of tumor cells by CD8 T cells. Another notable patent involves novel minor histocompatibility antigens (MiHAs), which are selected based on their minor allele frequency and tissue distribution. These MiHAs have potential applications in cancer immunotherapy, particularly for treating hematologic cancers such as leukemia.
Career Highlights
Claude Perreault has worked with prominent institutions, including the Université de Montréal and Rsem, Limited Partnership. His research has significantly advanced the understanding of tumor immunology and the development of targeted therapies.
Collaborations
Throughout his career, Perreault has collaborated with notable colleagues, including Pierre Thibault and Sébastien Lemieux. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
Claude Perreault's innovative work in cancer immunotherapy exemplifies the impact of scientific research on medical advancements. His patents and collaborations continue to pave the way for new therapeutic strategies in the fight against cancer.